There are 5 papers on CCL28 in aging research: 3 observational studies in people, 2 in animals.
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries.
“CCL28 was positively associated with PSMD (beta=0.01)”
None of its findings points the other way.
- 2 independent labs in 2 countries
- Funders: Bundesministerium für Forschung, Technologie und Raumfahrt and 5 more
- Humans3
- Animals2
Associations
2Peak width of skeletonized mean diffusivity
upin humans1
1 study
Peak width of skeletonized mean diffusivity
upin humans1
CCL28 is associated with peak width of skeletonized mean diffusivity in humans (beta=0.01, SE=0.002).
“CCL28 was positively associated with PSMD (beta=0.01)”
Humansblood
Plasma Proteomics and Sensitive Imaging Biomarkers of Vascular Brain Injury
medRxiv : the preprint server for health sciencesPreprint
Low muscle mass combined with high fat mass
upin humans1OR 1.32
1 study
Low muscle mass combined with high fat mass
upin humans1OR 1.32
CCL28 is associated with low muscle mass combined with high fat mass in humans (cross-sectional analysis) (OR 1.32 (95% CI 1.08-1.61)).
“CCL28 and metalloproteinase inhibitor 4 (TIMP4) constituted new biomarkers for the combination of low muscle and high fat mass [association with low ASMM combined with high BFMI: OR (95% CI): 1.32 (1.08-1.61)”
Humanscross-sectional analysisplasman = 1,478
Journal of cachexia, sarcopenia and muscle